medigraphic.com

2001, Number 2

<< Back Next >>

Rev Fac Med UNAM 2001; 44 (2)

Obesity: physiopathogenesis and treatment

Zárate A, Basurto AL, Saucedo GRP

Language: Spanish
References: 17
Page: 66-70
PDF size: 66.73 Kb.


Text Extraction

No abstract


REFERENCES

  1. Stehbens EW. The epidemiological relationship of hypercholesterolemia,hypertension, diabetes mellitus and obesity to coronary heart disease and atherogenesis. J Clin Epidemiol 1990; 43: 733-41.

  2. Liebel RL, Hirsh J. Metabolic characterization of obesity. Ann Int Med 1985; 103: 1000-02.

  3. Scwartz WM, Figlewicz PD, Baskin G, Woods CS, Porte D. Insulin and the central regulation of energy balance. Endocrine Rev 1994; 14: 109-18.

  4. Rouru JL, Antila L, Koskinen P, Penttila TA, Irjala K, Huuphonen R, Koulu M. Serum leptin concentrations in women with polycystic ovary syndrome, J Clin Endocrinol Metab 1997; 82: 1189-92.

  5. Ravussin E, Swinburn BA. Pathophysiology of obesity. Lancet 1992; 340: 404-08.

  6. Kennedy A, Gettys TW, Watson P, Wallace P, Ganaway E, Pan Q, Garvey T. The metabolic significance of leptin in humans: Genderbased differences in relationship to adiposity, insulin sensitivity, an energy expenditure. J Clin Endocrinol Metab 1997; 82: 1293-300.

  7. Cusin I, Dryden S, Wang Q, Rohner-Jeanrenaud F, Jeanrenaud F, Jeanrenaud B, Williams G. Effect of sustained physiological hyperinsulinaemia on hypothalamic neuropeptide Y and NPH mRNA levels in the rat, J Neuroendocrinol 1995; 7:193-7.

  8. Cohen B, Norvick D, Rubinstein M. Modulation of insulin activities by leptin. Science 1996; 274: 1185-8.

  9. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauser TL, Caro JF. Serum immunoreactive-leptin concentrations in normalweight and obese human. N Engl J Med 1996; 334: 292-5.

  10. Zárate A, Basurto L, Ochoa R. Una nueva hormona; la leptina, resucita la teoría genética de la obesidad. Ciencia 2000; 51: 5-11.

  11. Bray GA, York DA. Leptin and clinical medicine: A new piece in the puzzle of obesity. J Clin Endocrinol Metab 1997; 82: 2771-6.

  12. Mantzoros C. The role of leptin in human obesity and obesity disease: A review of current evidence. Ann Intern Med 1999; 130-671-80.

  13. Abenhaim L, Moride Y, Brenot F y cols. Appetite-supressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996; 335: 609-16.

  14. Garrow SJ. Treatment of obesity. Lancet 1992; 340: 409-13.

  15. Bray AG. Use and abuse of appetite-supresant drugs in the treatment of obesity. Ann Intern Med 1993; 119: 707-13.

  16. Toluminen S, Hietula M, Kuusankosky M. Double blind trial comparing fenfluramine, phentermine and dietary advice on treatment of obesity. Int J Obes 1990; 14 (Suppl 2): 138-44.

  17. Linner JH. Comparative effectiveness of gastric bypass and gastroplasty. Arch Surg 1982; 117: 695-700.




2020     |     www.medigraphic.com